

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

BUV737 Rat Anti-Mouse CD19

RRID:AB_2716855

Type: Antibody

Proper Citation

BD Biosciences Cat# 564296, RRID:AB_2716855

Antibody Information

URL: http://antibodyregistry.org/AB_2716855

Proper Citation: BD Biosciences Cat# 564296, RRID:AB_2716855

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: BUV737 Rat Anti-Mouse CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Clone ID: 1D3

Antibody ID: AB_2716855

Vendor: BD Biosciences

Catalog Number: 564296

Record Creation Time: 20231110T033802+0000

Record Last Update: 20260829T082806+0000

Ratings and Alerts

No rating or validation information has been found for BUV737 Rat Anti-Mouse CD19.

No alerts have been found for BUV737 Rat Anti-Mouse CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Onimus A, et al. (2026) Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion. Cell reports. Medicine, 7(5), 102788.

Chen R, et al. (2025) Transplants foster B cell alloimmunity by relaying extracellular vesicles to follicular dendritic cells. Cell reports, 44(6), 115832.

Hänggi K, et al. (2024) Interleukin-1 β release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. Cancer cell, 42(12), 2015.

Shreeve N, et al. (2021) The CD94/NKG2A inhibitory receptor educates uterine NK cells to optimize pregnancy outcomes in humans and mice. Immunity, 54(6), 1231.

de Mingo Pulido Á, et al. (2021) The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity, 54(6), 1154.

Jennings E, et al. (2020) Nr4a1 and Nr4a3 Reporter Mice Are Differentially Sensitive to T Cell Receptor Signal Strength and Duration. Cell reports, 33(5), 108328.

de Mingo Pulido Á, et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer cell, 33(1), 60.

Arce Vargas F, et al. (2018) Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer cell, 33(4), 649.

Sivick KE, et al. (2018) Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity. Cell reports, 25(11), 3074.